A Rare Opportunity? FDA Orphan Products Head Makes The Case For More Big Pharma Investment In Rare Diseases
Executive Summary
"Over the last 26 years, large pharmaceutical companies have missed an incredible opportunity," says Tim Coté, head of the Food & Drug Administration's Office of Orphan Product Development
You may also be interested in...
Rare Disease Drugs Need Faster Development Track, Sen. Brownback Tells FDA
Sen. Sam Brownback, R-Kansas, told FDA it should establish a second track for the development and approval of drugs for rare and neglected diseases
Rare Disease Drugs Need Faster Development Track, Sen. Brownback Tells FDA
Sen. Sam Brownback, R-Kansas, told FDA it should establish a second track for the development and approval of drugs for rare and neglected diseases
Pfizer Thinks Small: Partnership With Protalix On Gaucher Drug Eyes Cheaper Plant-Based Production
Pfizer's licensing deal with Protalix for global rights to the enzyme replacement therapy taliglucerase for the treatment of Gaucher disease, announced Dec. 1, signals the drug giant's interest in the orphan drug space. It also plays into the company's biosimilar strategy, given that taliglucerase will likely be positioned as a lower-cost alternative to Genzyme's Cerezyme (imiglucerase)